Back in March, a real-world analysis showed SGLT2 diabetes meds from AstraZeneca, Johnson & Johnson and the Eli Lilly-Boehringer team could dramatically cut heart failure hospitalizations and deaths. Now, new analyses confirm those findings—and may make a case for using the meds earlier in treatment, AZ’s execs suggest.

Bron: FiercePharma | lees verder..